Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Infrared Light Detects and Quantifies Malaria Parasites

By Labmedica International staff writers
Posted on 08 May 2014
Image: The Bruker Equinox 55 Fourier transform infrared spectrometer (Photo courtesy of Vienna University of Technology).
Image: The Bruker Equinox 55 Fourier transform infrared spectrometer (Photo courtesy of Vienna University of Technology).
A novel way to detect malaria, one of the most common and deadly diseases in the world, that also quantifies the early stage parasites, has been developed.

The quick and inexpensive test uses infrared light to detect malaria at a very early stage of its development by looking for fatty acids in the parasite and could dramatically reduce the number of people who die from the disease.

Scientists at Monash University (Clayton, VIC, Australia) maintained cultured Plasmodium falciparum parasites synchronized to ring stages by sorbitol lysis. High parasitemia ring-stage cultures were obtained by seeding uninfected red blood cells with purified schizont-stage parasites that were allowed to reinvade under shaking conditions overnight, reducing multiple infections.

The method to rapidly detect and quantify different stages of malaria parasites, including ring and gametocyte forms, used attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FT-IR) and partial least-squares regression (PLS). A Bruker model Equinox 55 (Bruker Optic; Ettingen, Germany) FT-IR spectrometer fitted with a nitrogen-cooled mercury–cadmium–telluride (MCT) detector and a golden gate diamond ATR accessory (Specac Limited; Orpington, UK) was used for spectral acquisition. ATR-FTIR utilizes infrared light to detect the vibrations of molecules and essentially depicts the entire chemistry of the system under investigation.

The scientists already knew that fatty acids were a marker for the disease from previous studies at the Australian Synchrotron. The Synchrotron allowed the team to see the different life stages of the parasite and the variation in its fatty acids. They then applied these insights to develop an inexpensive laboratory based test that has the potential to be portable. The results confirmed the ability of ATR-FT-IR to detect parasitaemia levels down to 0.00001%.

Bayden R. Wood, PhD, the senior author of the study, said, “Not only did the test give clear results within minutes, it gave a clear indication of malaria at a much earlier stage of infection than current tests on the market. Now that we can detect the early stages of a parasite's life in the blood stream the disease will be much easier to test and treat. The big advantage of our test is that it doesn't need scientists and expensive equipment. This has the potential to dramatically reduce the number of people dying from this disease in remote communities.” The study was published on April 2, 2014, in the journal Analytical Chemistry.

Related Links:

Monash University
Bruker Optic
Specac Limited



KARL HECHT GMBH & CO KG
DIASYS DIAGNOSTIC SYSTEMS
77 ELEKTRONIKA

Channels

Genetic Tests

view channel

Padlock Probe Assay Rapidly Detects Cardiac Disease Gene Mutations

A recent paper described a novel next generation sequencing (NGS) assay for detecting cardiac disease gene mutations with improved accuracy, flexibility, turnaround time, and cost. By using double-stranded DNA probes (complementary long "padlock" probes or cLPPs), investigators at Stanford University (Palo Alto, CA,... Read more

Hematology

view channel
Image: Immunochemistry of bone marrow biopsy from an acute myeloid leukemia patient showing sheets of CD34 positive cells; corresponding bone marrow aspirate showed only 20% blasts (Photo courtesy of All India Institute of Medical Sciences).

Immunohistochemistry Assesses Early Response in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to prognosis and early response assessment has an established role as predictor of remission rate, and overall and disease-free survival.... Read more

Industry News

view channel

Partners to Develop and Commercialize Noninvasive Tests for Bladder Cancer

An agreement between a major European university medical center and a multinational biotechnology company was designed to promote commercialization and further development of a liquid biopsy test for the diagnosis of bladder cancer. The liquid biopsy test is based on bladder cancer DNA methylation biomarkers developed... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.